Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.37 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.37 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2418753 | 0.81 | HTT (0.51) | HTTGRM2SMN1; SMN2CYP3A4CYP3A5 | |
| SCHEMBL28632092 | 0.80 | HTT (0.56) | HTTSMN1; SMN2KMT2ACHRNB4CHRNA3 | |
| SCHEMBL2411539 | 0.79 | HTT (0.49) | HTTGRM2SMN1; SMN2KMT2ACHRNB4 | |
| SCHEMBL1974134 | 0.77 | GRM2 (0.53) | HTTGRM2SMN1; SMN2KMT2ACHRNB2 | |
| Trifluoroacetic Acid SCHEMBL30901022 | 0.77 | CYP3A4 (0.51) | HTTGRM2SMN1; SMN2CYP3A4CYP3A5 | |
| SCHEMBL238960 | 0.76 | HTT (0.58) | HTTSMN1; SMN2KMT2ACHRNB4CHRNA3 | |
| SCHEMBL10002459 | 0.75 | HTT (0.54) | HTTSMN1; SMN2KMT2ACHRNB4CHRNA3 | |
| SCHEMBL6857473 | 0.75 | KMT2A (0.50) | SMN1; SMN2KMT2AMAPK1PLOD2PLOD3 | |
| SCHEMBL2413467 | 0.72 | MAPT (0.45) | GRM2SMN1; SMN2CHRNB2CHRNA4PLOD2 | |
| SCHEMBL5329081 | 0.72 | PLA2G7 (0.40) | HTTSMN1; SMN2MAPK1PLOD2PLOD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026239-B2 | Cell differentiation inducer | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-27 | — | — | US | disclosed |
| US-20100256201-A1 | CELL DIFFERENTIATION INDUCER | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-07 | — | — | US | disclosed |
| US-7687525-B2 | Cell differentiation inducer | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-30 | — | — | US | disclosed |
| US-20080188489-A1 | Cell differentiation inducer | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-08-07 | — | — | US | disclosed |
| US-7317028-B2 | Cell differentiation inducer | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-01-08 | — | — | US | disclosed |
| EP-1738752-A1 | Pharmaceutical combinations comprising cis-retine acid | Schering Aktiengesellschaft (DE) | 2007-01-03 | — | — | EP | disclosed |
| EP-1641458-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-04-05 | — | — | EP | disclosed |
| US-20050054647-A1 | New pharmaceutical combination | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-03-10 | — | — | US | disclosed |
| US-6794392-B1 | Cell differentiation inducer | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-09-21 | — | — | US | disclosed |
| US-20040147569-A1 | Antitumor agents; autoimmune disease; skin disorders; anticancer agents | SCHERING AKTIENGESELLSCHAFT | 2004-07-29 | — | — | US | disclosed |
| WO-2004058234-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | disclosed |
| EP-1437346-A1 | Benzamide derivatives useful as cell differentiation inducers | Schering AG (DE) | 2004-07-14 | — | — | EP | disclosed |
| US-6174905-B1 | AS CARCINOSTATIC AGENT TO A HEMATOLOGIC MALIGNANCY AND A SOLID CARCINOMA | MITSUI CHEMICALS, INC. (JP) | 2001-01-16 | — | — | US | disclosed |
| EP-0847992-A1 | Benzamide derivatives, useful as cell differentiation inducers | Mitsui Chemicals, Inc. (JP) | 1998-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188489-A1 | Cell differentiation inducer | MCL1, MYADM, MYD88 | HTT 4821/4885GRM2 4474/4885SMN1; SMN2 3895/4885 |
| US-20040147569-A1 | Antitumor agents; autoimmune disease; skin disorders; anticancer agents | MCL1, MYADM, PDCD1 | HTT 4492/4885GRM2 4740/4885SMN1; SMN2 2963/4885 |
| US-20100256201-A1 | CELL DIFFERENTIATION INDUCER | MCL1, MYADM, MYD88 | HTT 4810/4885GRM2 4507/4885SMN1; SMN2 3861/4885 |
| US-20050054647-A1 | New pharmaceutical combination | VEGFA, INHA, PGF | HTT 1790/4885GRM2 2224/4885SMN1; SMN2 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.